Compare DraftKings Inc (DKNG) vs Cassava Sciences Inc (FLNA) Price & Performance

DraftKings (DKNG) trades at $19.15, down 3.04% on the day and near its 52-week low of $18.95, reflecting bearish technical momentum. Fundamentally, revenue grew to $6.05 billion in 2025 with a slight net profit of $3.71 million, but recent quarterly EPS misses and a negative net income margin of -2.68% for 2026 highlight profitability challenges. The stock's high P/E of 246.33 signals premium valuation despite operational improvements, including positive operating cash flow of $662.86 million in 2025.

The outlook is mixed: strong analyst consensus (75% buy ratings) and a $33.13 price target suggest upside potential from sportsbook growth and prediction market expansion, but risks include competitive pressures, regulatory uncertainty from Brazil's betting ban, and volatility from high valuation multiples. Investors face a trade-off between long-term growth prospects and near-term earnings instability.

FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.

The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.